- Investor's Business Daily•11 hours ago
Biogen is slated early Tuesday to unveil its first-quarter earnings including a first look at sales of its $125,000 drug Spinraza.
- MarketWatch•11 hours ago
Spinraza’s price tag — up to $750,000 in the first year — has attracted criticism.
- Barrons.com•12 hours ago
Top holdings Biogen (BIIB) and Amgen (AMGN) have gained 1.95% and 1.56% ahead of earnings results, respectively. Alliance Bernstein analyst Ronny Gal has an Outperform rating on Biogen with a price target of $310, implying an upside of 12% from its recent price of $277. Gal details three things to watch for when Biogen reports tomorrow: MS sales.
BIIB : Summary for Biogen Inc. - Yahoo Finance
Biogen Inc. (BIIB)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||276.79 x 100|
|Ask||310.00 x 100|
|Day's Range||274.87 - 278.69|
|52 Week Range||223.02 - 333.65|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||16.35|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|